BioSig Technologies recently announced a ten-year strategic agreement with Mayo Clinic and Mayo Clinic Ventures. According to the press release, the agreement aims to advance clinical features of BioSig’s PURE EP System, which BioSig describes as a novel platform designed to obtain and display important clinical data during procedures that test the electrical activity of the heart, through close collaboration with leading Mayo electrophysiologists.  BioSig intends the collaboration to result in the development of future technologies.

Speaking of the agreement, Greg Cash, President and CEO of BioSig Technologies commented:

“Adding innovation and intellectual property to the equation should raise this collaboration to a whole new level, likely resulting in better diagnosis and treatment of complex arrhythmias in many patients.”

BioSig Technologies describes itself as a Minneapolis-based medical device company developing a platform for cardiac electrophysiology.  According to Yahoo! Finance, BioSig is publically traded over-the-counter and has a current market cap of about $36 million.

Mayo Clinic describes itself as a nonprofit organization committed to clinical practice, education, and research.